

IDS - 08/18/2006
AUG 18 2006
O I P E 1449A
PATENT & TRADEMARK OFFICE

PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/804,668
Sheet	1	of	3	Filing Date	March 19, 2004
				First Named Inventor	William A. Zoghbi
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	HO-P02680US1

U. S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
CB	AA	US-US 2003/0022235	01-30-2003	Dahlen et al.	
CB	AB	US-US 2003/0045908	03-06-2003	Condie et al.	
CB	AC	US-5,756,067	05-26-1998	Jones	
CB	AD	US-6,162,902	12/2000	Mischak et al.	
CB	AE	US-6,322,771	11-27-2001	Linden et al.	
CB	AF	US-6,376,207	04-23-2002	Nolan	
CB	AG	US-6,461,828	10-08-2002	Stanton, et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)			
CB	BA	WO-WO 2002089657	05-04-2002	Biosite, Inc.	T ⁶

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

¹Applicant's unique citation designation number (optional). ²See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
CB	CA	Axis-Shield - News Article - BNP TESTS 9/17/02 OTA#02/093, "New Test Used to Spot Heart Failure"; Dallas Business Journal, v25n11, 2001-10-06			
CB	CB	BERGER, R. ET AL, "B-Type Natriuretic Peptides (BNP and Pro-BNP) Predict Longterm Survival in Patients with Advanced Heart Failure Treated with Atenolol"; J Heart Lung Transplant. 20,251 (2001)			
CB	CC	BROCKHOFF C, ET AL; "Atrial natriuretic peptides: diagnostic and therapeutic potential" - Article in German - Abteilung fur Kardiologie, Universitätskrankenhaus Eppendorf, Hamburg, Germany; 4/8/2002			
CB	CD	CHO Y, ET AL.; "Natriuretic peptides and their therapeutic potential"; 4/8/2002; Department of Medicine, Brown University School of Medicine, Providence, Rhode Island, USA			
CB	CE	CLERICIO A, ET AL.; "Measurement of cardiac natriuretic hormones (atrial natriuretic peptide, brain natriuretic peptide, and related peptides) in a clinical practice: the need for a new generation of immunoassay methods"; Laboratory of Cardiovascular Endocrinology, Consiglio Nazionale delle Ricerche Institute of Clinical Physiology, University of Pisa, Pisa, Italy; 4/8/2002			
CB	CF	COWIE MR; "BNP: soon to become a routine measure in the care of patients with heart failure?"; 4/8/2002			
CB	CG	DE LEMOS, J.A., ET AL., "The Prognostic Value of B-Type Natriuretic Peptide in Patients with			

25535526 1	<i>Christina Bergest</i>	Date Considered	10/27/06
---------------	--------------------------	-----------------	----------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				<i>Complete if Known</i>	
				Application Number	10/804,668
				Filing Date	March 19, 2004
				First Named Inventor	William A. Zoghbi
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	2	of	3	Attorney Docket Number	HO-P02680US1

		Acute Coronary Syndromes"; N Engl J Med.. 345, 1014-21 (2001)			
CB	CH	DIAGNOSING HEART DISEASE (http://www.americanheart.org) September 17, 2002 - ABOUT RESEARCH; About VA R&D: News Releases About VA Research: Blood test for heart failure scores big in multinational trial			
CB	CI	DOOLITTLE, M.H. ET AL., "Immunodetection of Lipoprotein Lipase: Antibody Production, Immunoprecipitation, and Western Blotting Techniques"; Methods Mol Biol. 109, 215-371 (1999)			
CB	CJ	FISCHER, Y. ET AL., "Evaluation of a New, Rapid Bedside Test for Quantitative Determination of B-Type Natriuretic Peptide", Clin. Chem. 47, 591-594 (2001)			
CB	CK	JOURDAIN P, ET AL.; "Myocardial contractile reserve under low doses of dobutamine and improvement of left ventricular ejection fraction with treatment by carvedilol"; Service de Cardiologie Hopital R. Dubois, Pontoise, France; 11/21/2002			
CB	CL	KATO M, ET AL., "Augmented response in plasma brain natriuretic peptide to dynamic exercise in patients with left ventricular dysfunction and congestive heart failure."; 1st Department of Internal Medicine, Tottori University Faculty of Medicine, Yonago, Japan; 11/21/2002			
CB	CM	LATINI R, ET AL.; "What does the future hold for BNP in cardiology?"; 2/8/2002			
CB	CN	LEDER, ET AL.; "Myocardial ischemia and viability"; Clinic of Internal Medicine, Biomagnetic Centre, University of Jena, Jena, Germany (no date)			
CB	CO	MAIR J, ET AL.; "The impact of cardiac natriuretic peptide determination on the diagnosis and management of heart failure"; Department of Internal Medicine, University of Innsbruck School of Medicine, Austria; 4/8/2002			
CB	CP	MARUMOTO K, ET AL., "Increased secretion of atrial and brain natriuretic peptides during acute myocardial ischaemia induced by dynamic exercise in patients with angina pectoris"; Clin Sci (Lond); 88: 551-556 (1995)			
CB	CQ	MCNAIRY M, ET AL.; "Stability of B-type natriuretic peptide levels during exercise in patients with congestive heart failure: implications for outpatient monitoring with B-type natriuretic peptide." ; Division of Cardiology and the Department of Medicine, Veteran's Affairs medical Center and University of California, San Diego, California; 11/21/2002			
CB	CR	NAGEH T, ET AL.; "Interpretation of plasma brain natriuretic peptide concentrations may require adjustment for patient's age." ; 4/8/2002; Department of Cardiology, King's College Hospital, London, UK			
CB	CS	NAKAMURA M, ET AL.; "Value of plasma B type natriuretic peptide measurement for heart disease screening in a Japanese population"; 4/8/2002			
CB	CT	NICHOLSON S, ET AL.; "Atrial and brain natriuretic peptide response to exercise in patients with ischaemic heart disease"; 11/21/2002			
CB	CU	NISHIKIMI T, ET AL.; "Plasma brain natriuretic peptide levels in chronic hemodialysis patients: influence of coronary artery disease." ; Department of Hypertension and Cardiorenal Medicine, Dokkyo University School of Medicine, Mibu, Tochigi, Japan; 4/19/2002			
CB	CV	OHBA H, ET AL.; "Effects of prolonged strenuous exercise on plasma levels of atrial natriuretic peptide and brain natriuretic peptide in healthy men"; Department of Cardiology, St. Mariana University School of Medicine, Kanagawa, Japan; 4/19/2002			
CB	CW	OMLAND, T., "Plasma Brain Natriuretic Peptide as an Indicator of Left Ventricular Systolic Function and Long-term survival After Acute Myocardial Infarction", Circulation 1;93(11), 1963-9 (1996)			

25535526 .1	Christina Borgest	Date Considered	10/27/02
----------------	-------------------	-----------------	----------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/804,668
Sheet	3	of	3	Filing Date	March 19, 2004
				First Named Inventor	William A. Zoghbi
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	HO-P02680US1

<i>CN</i>	CX	PEACOCK WF 4TH; "The B-type natriuretic peptide assay: a rapid test for heart failure"; 4/8/2002	
<i>CB</i>	CY	STEIN, B., "Natriuretic peptides; Physiology, therapeutic potential, and risk stratification in ischemic heart disease"; C. Am Heart J. 135 (5Pt 1), 914-23 (1998)	
<i>CB</i>	CZ	VA Research Communications Service; "Quick Blood Test for Heart Failure Proves Successful in Multinational Trial"; Public Release Date 17 Jul 2002	
<i>CB</i>	CA1	VENUIGOPAL J; "Cardiac natriuretic peptides—hope or hype?"; Department of Physiology and Pharmacology, Strathclyde Institute of Biomedical Sciences, University of Strathclyde, Glasgow, UK; 4/8/2002	
<i>CB</i>	CB1	WAKU S, ET AL.; "Significance of brain natriuretic peptide measurement as a diagnostic indicator of cardiac function"; Kansai University, Health Administration Center, Osaka, Japan; 4/8/2002	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

25535526 .1	<i>Christina Borgest</i>	Date Considered	<i>CB</i>
----------------	--------------------------	-----------------	-----------